Inhaled insulins: The present and future of diabetes therapy

Current Medical Research and Opinion

Volumn 22, Issue SUPPL. 3, 2006, Pages

  Del Prato, Stefano ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

Diabetes complications; Diabetes mellitus, type 1; Diabetes mellitus, type 2; Efficacy; Insulin; Safety

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

CLINICAL TRIAL; DIABETES MELLITUS; DIET; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPNEA; EXERCISE; GLYCEMIC CONTROL; HEALTH CARE ORGANIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; THORAX PAIN;

EID: 33750550686     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132703     Document Type: Review

References (32)

1. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:997-86
2. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
3. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
4. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26 (Suppl 3):S18-24
5. Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-46
6. Liebl A, Mata M, Eschwege E, for the ODE-2 Advisory Board. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002;45:S23-8
7. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1998 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
8. Comi RJ. Treatment of type 2 diabetes mellitus: a weighty enigma. Ann Intern Med 2005;143:609-10
9. Patton J, Bukar J, Eldon M. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801
10. Heineman L, Heise T. Current states of the development of inhaled insulin. Br J Diabetes Vasc Dis 2004;4:295-301
11. Quattrin T, Bélanger A, Bohannon NJV, et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004;27:2622-7
12. Skyler JS, Weinstock RS, Raskin P, et al., for the Exubera Phase 3 Study Group. Use of inhaled insulin in a basal/bolus regimen in type 1 diabetic subjects. Diabetes Care 2005;28:1630-5
13. Norwood P, Dumas R, England RD, et al. Inhaled insulin (Exubera®) achieves tight glycemic control and is well tolerated in patients with type 1 diabetes. Diabetologia 2005;48 (Suppl 1):A30 [abstract 73]
14. Jovanovic L, Klioze S, Reis J, et al., for the Exubera 1022 Study Group. Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 1 diabetes (T1DM). Diabetes 2006;55 (Suppl 1):A26 [abstract 110-OR]
15. Garg S, Rosenstock J, Silverman BL, et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006;49:891-9
16. Edgerton DS, Neal DW, Scott M, et al. Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 2005;54:1164-70
17. Rosenstock J, Baughman RA, Rivera-Schaub T, et al. A randomized, double-blind, placebo-control study of the efficacy and safety of inhaled Technosphere insulin in patients with type 2 diabetes (T2DM). Diabetes 2005;54(Suppl 1):A88
18. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 2004;27:2356-62
19. Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162-7
20. Rosenstock J, Klioze S, Foyt H, et al., for the Exubera 1029 Study Group. Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes 2006;55 (Suppl 1):A26 [abstract 109-OR]
21. Barnett AH, Dreyer M, Lange P, et al. An open, randomized parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282-7
22. Barnett AH, Dreyer M, Lange P, et al. An open, randomized, parallel group study to compare the efficacy and safety profile of inhaled human insulin (Exubera®) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006;29:1818-25
23. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin (Exubera®) improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Ann Intern Med 2005;143:549-58
24. DeFronzo RA, Bergenstal RM, Cefalu WT, et al., for the Exubera Phase 3 Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 2005;28:1922-8
25. Hausman M, Dellweg S, Heinemann L, et al. Add-on therapy with Kos inhaled insulin is as efficacious as add-on therapy with Lantus in poorly controlled type 2 diabetic patients treated with sulfonylureas or metformin. Diabetologia 2005;48(Suppl 1): A297 [abstract 817]
26. Exubera® [US package insert]. New York, NY. Pfizer Labs, a division of Pfizer Inc; 2006
27. CO) in a multicentre clinical trial. Presented at the American Thoracic Society International Conference, May 20-25, 2005, San Diego, Calif, USA. Proc Am Thorac Soc 2005;2(Suppl) [abstract P2013]
28. Dreyer M, for the Exubera Phase 3 Study Group. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type diabetes patients poorly controlled with oral monotherapy. Presented at the 40th Annual Meeting of the European Association for the Study of Diabetes, September 5-9, 2004, Munich, Germany. Diabetologia 2004;47(Suppl 1):A44
29. Fineberg SE, Kawabata T, Finco-Kent D, et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera®) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-94
30. Rosenstock J, Cappelleri J, Bolinder B, et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera®) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-23
31. Hayes RP, Rosenstock J, Muchmore DM, et al. Patient-reported outcomes (PROs) using the Lilly/Alkermes inhaled insulin system versus injectable insulin in patients with type 1 diabetes (T1D). Diabetologia 2005;48(Suppl 1):A296 [abstract 815]
32. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28:427-8